Key Points
-
Evidence indicates that peritoneal dialysis (PD) is the most economically efficient dialysis modality, but is underused in many settings
-
Home haemodialysis (HD) might offer compelling advantages over in-centre HD, although these benefits may only be realized if patients move from in-centre to home HD
-
In developing nations, PD is generally similar or less costly than other dialysis modalities, and might become more attractive if optimized, for example, through local manufacturing of materials used in the procedure
-
Provision of dialysis therapy might not be the best use of the finite health-care resources available to low-income nations
-
Policies and incentives should be aligned with the economic efficiencies of dialysis to ensure sustainability of both the care of patients with end-stage renal disease and the health-care system overall
Abstract
The prevalence of chronic kidney disease and end-stage renal disease requiring dialysis therapy continues to increase worldwide, and despite technological advances, treatment remains resource intensive. Thus, the increasing burden of dialysis therapy on finite health-care budgets is an important consideration. The principles of allocative efficiency and the concept of 'opportunity cost' can be used to assess whether dialysis is economically justified; if dialysis is to be provided, cost-minimization and cost–utility analyses can be used to identify the most efficient dialysis modality. Existing studies have examined the cost, and where relevant the effectiveness, of the various currently available peritoneal dialysis and haemodialysis modalities. In this Review, we discuss variations in the intrinsic costs of the available dialysis modalities as well as other factors, such as variation by country, available health-care infrastructures, the timing of dialysis initiation and renal transplantation. We draw on data from robust micro-costing studies of the various dialysis modalities in Canada to highlight key issues.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lockridge, R. S. J. The direction of end-stage renal disease reimbursement in the United States. Semin. Dial. 17, 125–130 (2004).
Rettig, R. A. & Levinsky, N. G. Kidney failure and the federal government. National Academies Press [online], (1991).
Klarman, H. E., Francis, J. O. & Rosenthal, G. D. Cost effectiveness analysis applied to the treatment of chronic renal disease. Med. Care 6, 48–54 (1968).
Manns, B. J., Mendelssohn, D. C. & Taub, K. J. The economics of end-stage renal disease care in Canada: incentives and impact on delivery of care. Int. J. Health Care Finance Econ. 7, 149–169 (2007).
Hirth, R. The organization and financing of kidney dialysis and transplant care in the United States of America. Int. J. Health Care Finance Econ. 7, 301–318 (2007).
Rettig, R. A. The social contract and the treatment of permanent kidney failure. JAMA 275, 1123–1126 (1996).
United States Renal Data System. Annual Data Report 2002 Atlas of End-Stage Renal Disease in the United States [online], (2002).
Garella, S. The costs of dialysis in the U.S.A. Nephrol. Dial. Transplant. 12 (Suppl. 1), 10–21 (1997).
Tomson, C. R. Recent advances: nephrology. BMJ 320, 98–101 (2000).
Mallick, N. P. The costs of renal services in Britain. Nephrol. Dial. Transplant. 12 (Suppl. 1), 25–28 (1997).
Grosse, S. D. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev. Pharmacoecon. Outcomes Res. 8, 165–178 (2008).
US Census Bureau. Historical National Population Estimates [online], (2000).
Canadian Institute for Health Information. Canadian Organ Replacement Register Annual Report: Treatment of End-Stage Organ Failure in Canada, 2002 to 2011 [online], (2013).
United States Renal Data System. Annual Data Report: 2010 Atlas of End-Stage Renal Disease in the United States [online], (2012).
Moeller, S., Gioberge, S. & Brown, G. ESRD patients in 2001: global overview of patients, treatment modalities and development trends. Nephrol. Dial. Transplant. 17, 2071–2076 (2002).
Jain, A. K., Blake, P., Cordy, P. & Garg, A. X. Global trends in rates of peritoneal dialysis. J. Am. Soc. Nephrol. 23, 533–544 (2012).
Wild, S., Roglic, G., Green, A., Sicree, R. & King, H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047–1053 (2004).
Rosansky, S., Glassock, R. J. & Clark, W. F. Early start of dialysis: a critical review. Clin. J. Am. Soc. Nephrol. 6, 1222–1228 (2011).
Thomas, B. A. et al. The rapidly growing global burden of end-stage renal disease—an analysis of the change in maintenance dialysis prevalence between 1990 and 2010. [Abstract]. J. Am. Soc. Nephrol. 32A (2013).
Donaldson, C. & Shackley, P. in Economic Evaluation (eds Detels, R., Holland, W. W., McEwan, J. & Omenn, G. S.) (Oxford University Press, 1997).
Klarenbach, S. & Manns, B. Economic evaluation of dialysis therapies. Semin. Nephrol. 29, 524–532 (2009).
Haller, M. C., Vanholder, R., Oberbauer, R., Zoccali, C. & Van Biesen, W. Health economics and European Renal Best Practice—is it time to bring health economics into evidence-based guideline production in Europe? Nephrol. Dial. Transplant. http://dx.doi.org/10.1093/ndt/gft369.
Gerard, K. & Mooney, G. QALY league tables: handle with care. Health Econ. 2, 59–64 (1993).
Mauskopf, J., Rutten, F. & Schonfeld, W. Cost-effectiveness league tables: valuable guidance for decision makers? Pharmacoeconomics 21, 991–1000 (2003).
Drummond, M. F. Methods for the economic evaluation of health care programmes. (Oxford University Press, 1997).
Winkelmayer, W. C., Weinstein, M. C., Mittleman, M. A., Glynn, R. J. & Pliskin, J. S. Health economic evaluations: the special case of end-stage renal disease treatment. Med. Decis. Making 22, 417–430 (2002).
Goeree, R., Manalich, J., Grootendorst, P., Beecroft, M. L. & Churchill, D. N. Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clin. Invest. Med. 18, 455–464 (1995).
Lee, H. et al. Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am. J. Kidney Dis. 40, 611–622 (2002).
Chui, B. K. et al. Health care costs of peritoneal dialysis technique failure and dialysis modality switching. Am. J. Kidney Dis. 61, 104–111 (2013).
Shih, Y. C., Guo, A., Just, P. M. & Mujais, S. Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients. Kidney Int. 68, 319–329 (2005).
Karopadi, A. N., Mason, G., Rettore, E. & Ronco, C. Cost of peritoneal dialysis and haemodialysis across the world. Nephrol. Dial. Transplant. 28, 2553–2569 (2013).
Cortes-Sanabria, L. et al. Comparison of direct medical costs between automated and continuous ambulatory peritoneal dialysis. Perit. Dial. Int. 33, 679–686 (2013).
Liu, F. X., Quock, T. P., Burkart, J., Noe, L. L. & Inglese, G. Economic evaluations of peritoneal dialysis and hemodialysis: 2004–2012. F1000 Research 2, 273 (2013).
Korevaar, J. C. et al. Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. Kidney Int. 64, 2222–2228 (2003).
Lukowsky, L. R. et al. Comparing mortality of peritoneal and hemodialysis patients in the first 2 years of dialysis therapy: a marginal structural model analysis. Clin. J. Am. Soc. Nephrol. 8, 619–628 (2013).
Weinhandl, E. D. et al. Propensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patients. J. Am. Soc. Nephrol. 21, 499–506 (2010).
Schaubel, D. E., Morrison, H. I. & Fenton, S. S. Comparing mortality rates on CAPD/CCPD and hemodialysis. The Canadian experience: fact or fiction? Perit. Dial. Int. 18, 478–484 (1998).
Jaar, B. G. et al. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann. Intern. Med. 143, 174–183 (2005).
Fenton, S. S. et al. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am. J. Kidney Dis. 30, 334–342 (1997).
Foley, R. N. et al. Mode of dialysis therapy and mortality in end-stage renal disease. J. Am. Soc. Nephrol. 9, 267–276 (1998).
Bloembergen, W. E., Port, F. K., Mauger, E. A. & Wolfe, R. A. A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. J. Am. Soc. Nephrol. 6, 177–183 (1995).
Collins, A. J. et al. Mortality risks of peritoneal dialysis and hemodialysis. Am. J. Kidney Dis. 34, 1065–1074 (1999).
Klarenbach, S. et al. Economic evaluation of frequent home nocturnal hemodialysis based on a randomized controlled trial. J. Am. Soc. Nephrol. 25, 587–594 (2014).
McFarlane, P. A., Bayoumi, A. M., Pierratos, A. & Redelmeier, D. A. The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis. Kidney Int. 64, 1004–1011 (2003).
Kroeker, A. et al. An operating cost comparison between conventional and home quotidian hemodialysis. Am. J. Kidney Dis. 42, 49–55 (2003).
Agar, J. W. et al. Nocturnal haemodialysis: an Australian cost comparison with conventional satellite haemodialysis. Nephrology (Carlton) 10, 557–570 (2005).
McFarlane, P. & Komenda, P. Economic considerations in frequent home hemodialysis. Semin. Dial. 24, 678–683 (2011).
McFarlane, P. A., Pierratos, A. & Redelmeier, D. A. Cost savings of home nocturnal versus conventional in-center hemodialysis. Kidney Int. 62, 2216–2222 (2002).
Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada 3rd Edition [online], (2006).
Lee, C. P., Zenios, S. A. & Chertow, G. M. Cost-effectiveness of frequent in-center hemodialysis. J. Am. Soc. Nephrol. 19, 1792–1797 (2008).
Cooper, B. A. et al. A randomized, controlled trial of early versus late initiation of dialysis. N. Engl. J Med. 363, 609–619 (2010).
Harris, A. et al. Cost-effectiveness of initiating dialysis early: a randomized controlled trial. Am. J. Kidney Dis. 57, 707–715 (2011).
Nesrallah, G. E. et al. Canadian Society of Nephrology 2014 clinical practice guideline for timing the initiation of chronic dialysis. CMAJ 186, 112–117 (2014).
Culleton, B. F. et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 298, 1291–1299 (2007).
Rocco, M. V. et al. The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int. 80, 1080–1091 (2011).
Mohr, P. E. et al. The case for daily dialysis: its impact on costs and quality of life. Am. J. Kidney Dis. 37, 777–789 (2001).
Klarenbach, S. W., Heidenheim, A. P., Leitch, R. & Lindsay, R. M. Reduced requirement for erythropoietin with quotidian hemodialysis therapy. ASAIO J. 47, 153 (2001).
Wolfe, R. A. et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N. Engl. J. Med. 341, 1725–1730 (1999).
Laupacis, A. et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 50, 235–242 (1996).
Whiting, J. F. et al. Cost-effectiveness of organ donation: evaluating investment into donor action and other donor initiatives. Am. J. Transplant. 4, 569–573 (2004).
Barnieh, L. et al. A description of the costs of living and standard criteria deceased donor kidney transplantation. Am. J. Transplant. 11, 478–488 (2011).
Metzger, R. A. et al. Expanded criteria donors for kidney transplantation. Am. J. Transplant. 3 (Suppl. 4), 114–125 (2003).
Bingaman, A. W., Wright, F. H. & Murphey, C. L. Kidney paired donation in live-donor kidney transplantation. N. Engl. J. Med. 363, 1091–1092 (2010).
Park, W. D. et al. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am. J. Transplant. 3, 952–960 (2003).
de Wit, G. A., Ramsteijn, P. G. & de Charro, F. T. Economic evaluation of end stage renal disease treatment. Health Policy 44, 215–232 (1998).
Cueto-Manzano, A. M. & Rojas-Campos, E. Status of renal replacement therapy and peritoneal dialysis in Mexico. Perit. Dial. Int. 27, 142–148 (2007).
Canadian Institute for Health Information. Canadian Organ Replacement Register Annual Report: Treatment of End-Stage Organ Failure in Canada, 2003 to 2012 [online], (2014).
United States Renal Data System. Annual Data Report: 2008 Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States [online], (2008).
Neil, N. et al. Gaining efficiencies: resources and demand for dialysis around the globe. Value Health 12, 73–79 (2008).
Mendelssohn, D. C. et al. A prospective evaluation of renal replacement therapy modality eligibility. Nephrol. Dial. Transplant. 24, 555–561 (2009).
Just, P. M. et al. Reimbursement and economic factors influencing dialysis modality choice around the world. Nephrol. Dial. Transplant. 23, 2365–2373 (2008).
Chow, K. M. & Li, P. K.-T. Choice of dialysis—what to do with economic incentives. Nat. Rev. Nephrol. 8, 495–496 (2012).
Blagg, C. R. Dialysis composite rate bundling: potential effects on the utilization of home hemodialysis, daily and nocturnal hemodialysis, and peritoneal dialysis. Semin. Dial. 24, 674–677 (2011).
Li, P. K.-T. & Chow, K. M. Peritoneal dialysis-first policy made successful: perspectives and actions. Am. J. Kid. Dis. 62, 993–1005 (2013).
[No authors listed] Medical professionalism in the new millennium: a physicians' charter. Lancet 9, 520–522 (2002).
International Monetary Fund. World Economic Outlook Database, April 2014: Report for Selected Countries and Subjects [online], (2014).
Acknowledgements
S.W.K., M.T. and B.J.M. have received career salary awards from the Alberta Heritage Foundation for Medical Research/Alberta Innovates Health Solutions. The work of S.W.K., M.T., B.C. and B.J.M. is supported by a joint initiative between Alberta Health and Wellness and the Universities of Alberta and Calgary. The work of M.T. is also supported by a Government of Canada Research Chair focused on the optimal care of people with chronic kidney disease.
Author information
Authors and Affiliations
Contributions
S.W.K. and M.T. made substantial contributions to discussion of content, S.W.K. researched the data and wrote the article. All authors reviewed and/or edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Klarenbach, S., Tonelli, M., Chui, B. et al. Economic evaluation of dialysis therapies. Nat Rev Nephrol 10, 644–652 (2014). https://doi.org/10.1038/nrneph.2014.145
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2014.145
This article is cited by
-
SAGES peritoneal dialysis access guideline update 2023
Surgical Endoscopy (2024)
-
Health related quality of life during dialysis modality transitions: a qualitative study
BMC Nephrology (2023)
-
Effect of dialysis modalities on risk of hospitalization for gastrointestinal bleeding
Scientific Reports (2023)
-
Healthcare costs after kidney transplantation compared to dialysis based on propensity score methods and real world longitudinal register data from Sweden
Scientific Reports (2023)
-
Identifying the barriers to kidney transplantation for patients in rural and remote areas: a scoping review
Journal of Nephrology (2023)